Carbamazepine adjunct for nonresponsive psychosis with prior hallucinogenic abuse.
Some patients diagnosed as schizophrenic report persistent polymodal hallucinosis following a period of extensive hallucinogenic drug abuse unrelieved by the usual antipsychotic drugs. In this open study, carbamazepine (Tegretol, an anticonvulsant) was administered to three patients with polymodal hallucinosis which had failed to diminish on antipsychotic drugs alone. All three patients showed a marked to complete reduction in symptomatology.
Scher
M
M
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.
Neppe
V
V
D000328:Adult; D000437:Alcoholism / Q000150:complications / Q000188:drug therapy; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002220:Carbamazepine / Q000008:administration & dosage / Q000627:therapeutic use*; D002707:Chlordiazepoxide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006212:Hallucinations / Q000139:chemically induced / Q000188:drug therapy; D006213:Hallucinogens; D006801:Humans; D008297:Male; D011605:Psychoses, Substance-Induced / Q000188:drug therapy*; D012559:Schizophrenia / Q000139:chemically induced / Q000188:drug therapy; D019966:Substance-Related Disorders / Q000150:complications; D013997:Time Factors
D014150:Antipsychotic Agents; D006213:Hallucinogens; D002220:Carbamazepine; D002707:Chlordiazepoxide